The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease ...

Analyst Michael Ulz from Morgan Stanley reiterated a Buy rating on Dyne Therapeutics (DYN – Research Report) and keeping the price target ...

Avidity Biosciences stock surges on expansion of pipeline targeting rare genetic cardiomyopathies and improvements in siRNA ...

CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that ...

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) has been given a consensus rating of “Buy” by the ten ratings firms ...

Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Dyne Therapeutics (DYN – Research Report) and keeping the price ...

Detailed price information for Design Therapeutics Inc (DSGN-Q) from The Globe and Mail including charting and trades.

Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy ...

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, today announced an oral presentation at the upcoming ...

Avidity will need deep pockets, though, as it has other clinical-stage projects on the go, including a phase 3 trial (HARBOR) of its lead del-desiran (AOC 1001) candidate for myotonic dystrophy ...

This upside in RNA stock is being driven by the encouraging clinical development of its three rare neuromuscular programs — ...

"Ringed" fibers are sometimes seen in Duchenne's dystrophy, but they are more frequent in myotonic dystrophy. Whether the large numbers of "ringed" fibers are characteristic for this form of ...